SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain ...
13h
ClearPoint forecasts $52m-$56m 2026 revenue range as IRRAflow could be cash neutral as early as 2027
“Gross margin for the first quarter of 2026 was 64%,” while cash and cash equivalents were “$35.6 million as compared to $45.9 million at December 31, 2025,” with the reduction “primarily due to the ...
Global Commercial Footprint -- Over 175 active sites are currently using ClearPoint technology, with expectations to surpass ...
Zacks Investment Research on MSN
ClearPoint Neuro, Inc. (CLPT) reports Q1 loss, lags revenue estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.22 per share a year ago. These ...
MarketBeat on MSN
ClearPoint Neuro Q1 earnings call highlights
ClearPoint Neuro (NASDAQ:CLPT) reported record first-quarter 2026 revenue and reaffirmed its full-year outlook, as management ...
ClearPoint faces pressure from weak 2026 guidance and regulatory uncertainty, but partner therapy launches could drive revenue. See more on CLPT stock.
SOLANA BEACH, CA / ACCESS Newswire / April 29, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...
ClearPoint Neuro (NASDAQ:CLPT) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript ...
Surgical Centres Inc., a subsidiary of Clearpoint Health Network, currently handles thousands of surgeries completed in ...
SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results